Die asymptomatische Karotisstenose: Was ist neu?

Was ist neu?

Indikation zur Revaskularisation asymptomatischer Karotisstenosen Mit einer optimalen medikamentösen Therapie kann eine vergleichbare Risikoreduktion wie mit einer Revaskularisation erreicht werden. Daher empfiehlt die aktualisierte S3-Leitlinie, die Indikation zur Revaskularisation einer asymptomatischen hochgradigen Karotisstenose unter sorgfältiger Risiko-Nutzen-Abwägung individualisiert zu treffen. Voraussetzung ist, dass kein erhöhtes Operationsrisiko besteht und ein oder mehrere klinische oder bildgebende Befunde vorliegen, die mit einem erhöhten Schlaganfallrisiko assoziiert sind. Die periprozedurale Schlaganfallrate/Letalität soll maximal 2 % betragen.

Optimierte konservative Therapie (BMT) Die Einnahme von ASS (100 mg/Tag) führt bei Patienten mit asymptomatischer Karotisstenose zu einer signifikanten Reduktion der 5-Jahres-Mortalität auch nach Adjustierung für andere Risikofaktoren. Ein LDL-Zielwert < 70 mg/dl führt im Vergleich zu einem Zielwert von 90–110 mg/dl zu einer signifikant größeren Reduktion der Intima-Media-Dicke.

Abstract

In industrialized countries, stroke is still the most common disease that leads to permanent disability. Of the 250 000 strokes that occur annually in Germany, in about 80 % are cerebral ischemia. Approximately 15 % of these ischemias are caused by lesions of the extracranial internal carotid artery, so optimal treatment of extracranial carotid stenosis is essential [1]. This continues to be the subject of a controversial debate, as optimized drug therapy has led to a significant reduction in risk.

In 2020, the multidisciplinary S3 guideline for the management of extracranial carotid stenoses was updated. In the following, current aspects and new recommendations for asymptomatic carotid stenosis are presented and important innovations of the guideline are explained.

Schlüsselwörter

Karotisstenose - Schlaganfall - Leitlinie - konservative Therapie - Revaskularisation

Key words

carotid stenosis - stroke - guideline - best medical treatment - revaskularisation

Publication History

Article published online:
29 March 2021

• Literatur

• 1 Spence JD. Asymptomatic Carotid Stenosis: High Risk with Suboptimal Treatment. Eur J Vasc Endovasc 2020; 59: 151
• 2 Eckstein HH, Kühnl A, Berkefeld J. et al Diagnostik, Therapie und Nachsorge der extrakraniellen Karotisstenose. Dtsch Arztebl Int 2020; 117: 801-807 . doi:10.3238/arztebl.2020.0801
• 3 Johal AS, Loftus IM, Boyle JR. et al. Changing Patterns of Carotid Endarterectomy Between 2011 and 2017 in England. Stroke 2019; 50: 2461-2468
• 4 Fabiani I, Palombo C, Caramella D. et al. Imaging of the vulnerable carotid plaque: Role of imaging techniques and a research agenda. Neurology 2020; 94: 922-932
• 5 Keyhani S, Madden E, Cheng EM. et al. Risk Prediction Tools to Improve Patient Selection for Carotid Endarterectomy Among Patients with Asymptomatic Carotid Stenosis. Jama Surg 2019; 154: 336
• 6 Kelly PJ, Camps-Renom P, Giannotti N. et al. Carotid Plaque Inflammation Imaged by 18F-Fluorodeoxyglucose Positron Emission Tomography and Risk of Early Recurrent Stroke. Stroke 2019; 50: 1766-1773
• 7 Li J, Li D, Yang D. et al. Irregularity of Carotid Plaque Surface Predicts subsequent Vascular Event: A MRI Study. J Magnetic Reson Imaging Jmri 2020; 52: 185-194
• 8 Reiff T, Eckstein H, Mansmann U. et al. Angioplasty in asymptomatic carotid artery stenosis vs. endarterectomy compared to best medical treatment: One-year interim results of SPACE-2. Int J Stroke 2019; DOI: 174749301983301.
• 9 Keyhani S, Cheng EM, Hoggatt KJ. et al. Comparative Effectiveness of Carotid Endarterectomy vs Initial Medical Therapy in Patients with Asymptomatic Carotid Stenosis. Jama Neurol 2020; 77: 1110-1121
• 10 Cui L, Han Y, Zhang S. et al. Safety of Stenting and Endarterectomy for Asymptomatic Carotid Artery Stenosis: A Meta-Analysis of Randomised Controlled Trials. Eur J Vasc Endovasc 2018; 55: 614-624
• 11 Eckstein HH, Tsantilas P, Kühnl A. et al. Surgical and Endovascular Treatment of Extracranial Carotid Stenosis. Deutsches Aerzteblatt Online 2017; 114: 729-736
• 12 Brott TG, Calvet D, Howard G. et al. Long-term outcomes of stenting and endarterectomy for symptomatic carotid stenosis: a preplanned pooled analysis of individual patient data. Lancet Neurology 2019; 18: 348-356
• 13 Batchelder AJ, Saratzis A, Naylor AR. Overview of Primary and Secondary Analyses From 20 Randomised Controlled Trials Comparing Carotid Artery Stenting with Carotid Endarterectomy. Eur J Vasc Endovasc 2019; 58: 479-493
• 14 Schermerhorn ML, Liang P, Eldrup-Jorgensen J. et al. Association of Transcarotid Artery Revascularization vs Transfemoral Carotid Artery Stenting With Stroke or Death Among Patients With Carotid Artery Stenosis. Jama 2019; 322: 2313-2322
• 15 Kashyap VS, Schneider PA, Foteh M. et al. Early Outcomes in the ROADSTER 2 Study of Transcarotid Artery Revascularization in Patients With Significant Carotid Artery Disease. Stroke 2020; 51: STROKEAHA120030550
• 16 Coelho A, Prassaparo T, Mansilha A. et al. Critical Appraisal on the Quality of Reporting on Safety and Efficacy of Transcarotid Artery Stenting with Flow Reversal. Stroke 2020; 51: STROKEAHA120030283
• 17 Giannopoulos A, Kakkos S, Griffin M. et al. Mortality risk stratification in patients with asymptomatic carotid stenosis. Vasc Investigation Ther 2019; 2: 25
• 18 Amarenco P, Kim JS, Labreuche J. et al. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. New Engl J Medicine 2019; 382: 9
• 19 Amarenco P, Hobeanu C, Labreuche J. et al. Carotid Atherosclerosis Evolution when Targeting a Low-Density Lipoprotein Cholesterol Concentration < 70 mg/dL after an Ischemic Stroke of Atherosclerotic Origin. Circulation 2020; 142: 748-757